N/A
N=1,201
5-Cog Battery for Detecting Cognitive Impairment and Dementia
Dementia · Cognitive Impairment · Mild Cognitive Impairment · Neurocognitive Disorders
Bottom Line
View on ClinicalTrials.gov: NCT03816644 ↗Enrolled (actual)
1,201
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: New Occurrence in Dementia Care-A Composite Endpoint Including New Cognitive Diagnoses, Laboratory Investigations Related to Cognitive Impairment, New Dementia Prescriptions, and Cognitive Related Referrals. — 111; 41 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 5-Cog (Other); Health Literacy & Grip Assessment (Other)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- Albert Einstein College of Medicine
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY New Occurrence in Dementia Care-A Composite Endpoint Including New Cognitive Diagnoses, Laboratory Investigations Related to Cognitive Impairment, New Dementia Prescriptions, and Cognitive Related Referrals. |
111; 41 | — |
| SECONDARY New Occurrence of in Health Care Utilization |
106; 96 | — |
Summary
Despite the availability of numerous cognitive assessment tools, cognitive impairment related to dementia is frequently under-diagnosed in primary care settings. The investigators have developed a 5-minute cognitive screen (5-Cog) coupled with a decision tree to overcome the technical, cultural and logistic barriers of current cognitive screens to improve dementia care in primary care patients with cognitive concerns.
Eligibility Criteria
Inclusion Criteria
- Age 65 and older.
- Presence of cognitive or memory concerns expressed by patient, caregiver, health care provider or other source who knows the patient.
- Registered as patient at Montefiore Medical Center and have a primary care doctor appointment that day.
- Able to hear and see well enough to complete intervention or control assessments.
- English or Spanish speaking.
Exclusion Criteria
- Prior diagnosis of dementia or MCI as ascertained by ICD-10 codes or the documentation of prescription for anti-dementia medications in EMR. Patients with a diagnosis containing any of the following terms will be excluded:
- "Dementia"
- "Mild Cognitive Impairment"
- "Alzheimer's Disease"
- "Creutzfeldt-Jakob Disease"
- "Major Neurocognitive Disorder"
- "Minor Neurocognitive Disorder"
Patients with any of the following medications documented in their EMR will be excluded (generic = brand):
- Donepezil = Aricept
- Memantine = Namenda
- Rivastigmine = Exelon
- Galantamine = Razadyne
- Donepezil and Memantine = Namzaric
- Adults who are permanent residents of a nursing facility.
- Patients who do not speak English or Spanish.
- Patients who are not seeing a primary care physician at the clinic that day.
- Patients who are blind or deaf or cannot hear loud voice even with hearing aids.
Data sourced from ClinicalTrials.gov (NCT03816644). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.